ANNUAL GENERAL MEETING OF SHAREHOLDERS IN SIMRIS ALG AB (PUBL)

The annual general meeting of Simris Alg AB (publ) was held on Wednesday, 25 May 2022. At the meeting 11,040,502 B-shares were represented, which corresponds to approx. 11.3 percent of the total number of B-shares. The summary below shows the resolutions adopted at the AGM. The resolutions were adopted unanimously.

Allocation of the company’s result
The AGM approved the board’s proposal that the result should be carried forward.

Fees to the board members and the auditors
The AGM agreed on the following fees to the board and the auditors.

Chairman – 140,000 SEK
Each one of the board members elected by the AGM (and who are not employed in the group) – 70,000 SEK
Fees to the auditors shall be paid in accordance with approved invoices.

Board members, chairman of the board and auditors
Magnus Högström, Steven Schapera, Frank Puccio and Robert Quandt were re-elected as board members. Steven Schapera was re-elected as chairman of the board.

Ernst & Young AB was elected as the company’s auditor, with Peter Gunnarsson as auditor in charge.

Authorization for the board to decide on issue of new shares, convertibles and/or warrants
The AGM resolved to authorize the board of Simris Alg AB to decide to issue new shares of class A or B in the company and/or convertibles and/or warrants, in accordance with the board’s proposal.

Issue of warrants to board members
The major shareholders Erik Karlsson and Bengt Johansson chose to withdraw their proposal.

Issue of warrants to key employees
The board chose to withdraw its proposal.

Guiding principles for election committee
The AGM confirmed the guidelines for the election committee in accordance with the board’s proposal.

For further information, please contact:
Steven Schapera, chairman, Simris Alg AB
Tel: +44 791 771 5533, e-mail: steven@simris.com

About Simris Alg
Simris Alg is a pioneering biotechnology company dedicated to the enormous potential of microalgae in the discovery and production of high-quality bioactive substances and alternatives to unsustainable marine ingredients. We are engaged in research, development, and production of bioactive substances from microalgae, for nutraceutical, cosmetic and pharmaceutical applications. Our technology provides access to bioactive substances with new functions, while at the same time replacing unsustainable raw materials from endangered marine species and ecosystems.

Simris Alg’s share is traded on Nasdaq First North Growth Market with the ticker SIMRIS and ISIN-code SE0008091664. Mangold Fondkommission AB is the Company’s Certified Adviser, reachable by tel: 08-503 015 50 and email: ca@mangold.se.